CN102414180A - 作为沉默调节蛋白调节剂的8-取代的喹啉及相关的类似物 - Google Patents
作为沉默调节蛋白调节剂的8-取代的喹啉及相关的类似物 Download PDFInfo
- Publication number
- CN102414180A CN102414180A CN2010800194505A CN201080019450A CN102414180A CN 102414180 A CN102414180 A CN 102414180A CN 2010800194505 A CN2010800194505 A CN 2010800194505A CN 201080019450 A CN201080019450 A CN 201080019450A CN 102414180 A CN102414180 A CN 102414180A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- substituted
- fluorine
- heterocycle
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 C*C(C1=*C(*C=C*=CC)=N)=NN=CC1=I* Chemical compound C*C(C1=*C(*C=C*=CC)=N)=NN=CC1=I* 0.000 description 7
- RVPUQJZGLZPNAC-UHFFFAOYSA-N Oc(ccc1ncc2)nc1c2-c1cccc(C(F)(F)F)c1 Chemical compound Oc(ccc1ncc2)nc1c2-c1cccc(C(F)(F)F)c1 RVPUQJZGLZPNAC-UHFFFAOYSA-N 0.000 description 2
- ATWXYVDFJLESJV-UHFFFAOYSA-N CC1(C)OB(c2cccc(N3CCCC3)c2)OC1(C)C Chemical compound CC1(C)OB(c2cccc(N3CCCC3)c2)OC1(C)C ATWXYVDFJLESJV-UHFFFAOYSA-N 0.000 description 1
- CVCCJLPOKYIQGF-UHFFFAOYSA-N CC1(C)OC(COC2=CC(NC(c(ccc3ccc4)nc3c4-c3cccc(C(F)(F)F)c3)=O)=CCC2)CO1 Chemical compound CC1(C)OC(COC2=CC(NC(c(ccc3ccc4)nc3c4-c3cccc(C(F)(F)F)c3)=O)=CCC2)CO1 CVCCJLPOKYIQGF-UHFFFAOYSA-N 0.000 description 1
- OPYFNQCMGLDHKD-UHFFFAOYSA-N COC(c(ccc1ncc2)nc1c2-c1cc(C(F)(F)F)ccc1)=O Chemical compound COC(c(ccc1ncc2)nc1c2-c1cc(C(F)(F)F)ccc1)=O OPYFNQCMGLDHKD-UHFFFAOYSA-N 0.000 description 1
- HWPUUXMDFWSFKV-UHFFFAOYSA-N Cc(ccc1ccc2)nc1c2-c1cc(C(F)(F)F)ccc1 Chemical compound Cc(ccc1ccc2)nc1c2-c1cc(C(F)(F)F)ccc1 HWPUUXMDFWSFKV-UHFFFAOYSA-N 0.000 description 1
- NWOHVQVBCFDBBP-UHFFFAOYSA-N Cc1cc([F]C)cc(F)c1 Chemical compound Cc1cc([F]C)cc(F)c1 NWOHVQVBCFDBBP-UHFFFAOYSA-N 0.000 description 1
- ALHUXMDEZNLFTA-UHFFFAOYSA-N Cc1cnc(cccc2)c2n1 Chemical compound Cc1cnc(cccc2)c2n1 ALHUXMDEZNLFTA-UHFFFAOYSA-N 0.000 description 1
- DXPQTHAFYUTZRR-UHFFFAOYSA-N Cc1nc(cccc2)c2cn1 Chemical compound Cc1nc(cccc2)c2cn1 DXPQTHAFYUTZRR-UHFFFAOYSA-N 0.000 description 1
- CGSWTRTYXLGAFI-UHFFFAOYSA-N Cc1nc(nccc2)c2[s]1 Chemical compound Cc1nc(nccc2)c2[s]1 CGSWTRTYXLGAFI-UHFFFAOYSA-N 0.000 description 1
- CHDYZMKVWALTSP-UHFFFAOYSA-N O=Cc(ccc1ccc2)nc1c2-c1cc(C(F)(F)F)ccc1 Chemical compound O=Cc(ccc1ccc2)nc1c2-c1cc(C(F)(F)F)ccc1 CHDYZMKVWALTSP-UHFFFAOYSA-N 0.000 description 1
- VFMDKVCKSXMQHK-UHFFFAOYSA-N OC(c(ccc1ccc2)nc1c2-c1cc(N2CCCC2)ccc1)=O Chemical compound OC(c(ccc1ccc2)nc1c2-c1cc(N2CCCC2)ccc1)=O VFMDKVCKSXMQHK-UHFFFAOYSA-N 0.000 description 1
- XVPVPIRVAPAANV-UHFFFAOYSA-N OCC(COc1cccc(NC(c2nc(c(-c3cccc(C(F)(F)F)c3)ccc3)c3cc2)=O)c1)O Chemical compound OCC(COc1cccc(NC(c2nc(c(-c3cccc(C(F)(F)F)c3)ccc3)c3cc2)=O)c1)O XVPVPIRVAPAANV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15674909P | 2009-03-02 | 2009-03-02 | |
US61/156,749 | 2009-03-02 | ||
PCT/US2010/025963 WO2010101949A1 (en) | 2009-03-02 | 2010-03-02 | 8-substituted quinolines and related analogs as sirtuin modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102414180A true CN102414180A (zh) | 2012-04-11 |
Family
ID=42709991
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010800194505A Pending CN102414180A (zh) | 2009-03-02 | 2010-03-02 | 作为沉默调节蛋白调节剂的8-取代的喹啉及相关的类似物 |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP2403833A4 (ko) |
JP (1) | JP2012519211A (ko) |
KR (1) | KR20110128908A (ko) |
CN (1) | CN102414180A (ko) |
AU (1) | AU2010221417A1 (ko) |
BR (1) | BRPI1011477A2 (ko) |
CA (1) | CA2754058A1 (ko) |
EA (1) | EA201171098A1 (ko) |
IL (1) | IL214943A0 (ko) |
MX (1) | MX2011009213A (ko) |
WO (1) | WO2010101949A1 (ko) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104592109A (zh) * | 2015-01-19 | 2015-05-06 | 湖南华腾制药有限公司 | 一种8-溴喹啉衍生物的制备方法 |
CN105143222A (zh) * | 2013-03-14 | 2015-12-09 | 默克专利有限公司 | 糖苷酶抑制剂 |
CN105764901A (zh) * | 2013-11-12 | 2016-07-13 | 豪夫迈·罗氏有限公司 | 作为用于治疗神经变性疾病的神经源性药的吡啶并[4,3-b]吡嗪-2-甲酰胺 |
CN110964011A (zh) * | 2019-12-16 | 2020-04-07 | 诚达药业股份有限公司 | 一种8-氯-1,7-萘啶-3-甲醛的合成方法 |
CN117362286A (zh) * | 2023-12-08 | 2024-01-09 | 清华大学 | 具有sirt6激动活性的化合物及其用途 |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2723135A1 (en) | 2008-05-01 | 2009-11-05 | Sirtris Pharmaceuticals, Inc. | Quenolines and related analogs as sirtuin modulators |
US8846947B2 (en) | 2008-07-03 | 2014-09-30 | Glaxosmithkline Llc | Benzimidazoles and related analogs as sirtuin modulators |
AU2009295948B2 (en) | 2008-09-29 | 2013-12-05 | GlaxoSmithKline, LLC | Quinazolinone, quinolone and related analogs as sirtuin modulators |
IN2012DN03799A (ko) | 2009-10-29 | 2015-08-28 | Sirtris Pharmaceuticals Inc | |
US8604032B2 (en) | 2010-05-21 | 2013-12-10 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
DK2686303T3 (en) | 2011-03-18 | 2016-03-29 | Bayer Ip Gmbh | N- (3-carbamoylphenyl) -1 H -pyrazole-5-carboxamide derivatives and their use for controlling animal pests |
CN102250151B (zh) * | 2011-05-17 | 2013-11-06 | 中国科学院化学研究所 | 2-芳亚胺-8-苯并咪唑喹啉过渡金属配合物及其制备方法与应用 |
EP2751093A1 (en) | 2011-08-29 | 2014-07-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CA2852937A1 (en) * | 2011-10-20 | 2013-04-25 | Glaxosmithkline Llc | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators |
WO2013059587A1 (en) | 2011-10-20 | 2013-04-25 | Sirtris Pharmaceuticals, Inc. | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators |
WO2013135671A1 (en) | 2012-03-13 | 2013-09-19 | Basf Se | Fungicidal pyrimidine compounds |
JP2016505534A (ja) * | 2012-11-20 | 2016-02-25 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 置換1,6−ナフチリジン |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
US9776997B2 (en) | 2013-06-04 | 2017-10-03 | Bayer Pharma Aktiengesellschaft | 3-aryl-substituted imidazo[1,2-A]pyridines and their use |
TWI529171B (zh) * | 2013-07-29 | 2016-04-11 | 赫孚孟拉羅股份公司 | 1,7-萘啶衍生物 |
WO2015036059A1 (en) | 2013-09-16 | 2015-03-19 | Basf Se | Fungicidal pyrimidine compounds |
WO2015036058A1 (en) | 2013-09-16 | 2015-03-19 | Basf Se | Fungicidal pyrimidine compounds |
US10172915B2 (en) | 2013-10-20 | 2019-01-08 | Duke University | Methods and compositions for activation of sirtuins with Annexin A1 peptides |
JP6112724B2 (ja) * | 2013-10-31 | 2017-04-12 | 日本化薬株式会社 | 1,5−ナフチリジン誘導体およびそれを有効成分として含んでなる殺虫剤 |
TW201612161A (en) | 2014-01-20 | 2016-04-01 | Bayer Cropscience Ag | Quinoline derivatives as insecticides and acaricides |
EP3107920B1 (de) | 2014-02-19 | 2017-10-18 | Bayer Pharma Aktiengesellschaft | 3-(pyrimidin-2-yl)imidazo[1,2-a]pyridine |
AU2015261775B2 (en) | 2014-05-23 | 2019-07-11 | Active Biotech Ab | Novel compounds useful as S100-inhibitors |
WO2016009076A1 (en) * | 2014-07-17 | 2016-01-21 | Merck Patent Gmbh | Novel naphthryidines and isoquinolines and their use as cdk8/19 inhibitors |
KR20170038877A (ko) | 2014-08-01 | 2017-04-07 | 누에볼루션 에이/에스 | 브로모도메인에 대하여 활성을 갖는 화합물 |
JP6563017B2 (ja) | 2014-08-28 | 2019-08-21 | エースニューロン・ソシエテ・アノニム | グリコシダーゼ阻害剤 |
EP3227287B1 (de) | 2014-12-02 | 2019-08-07 | Bayer Pharma Aktiengesellschaft | Heteroaryl-substituierte imidazo[1,2-a]pyridine und ihre verwendung |
CA2974874A1 (en) * | 2015-02-11 | 2016-08-18 | Basilea Pharmaceutica International AG | Substituted mono- and polyazanaphthalene derivatives and their use |
AU2017222964B2 (en) | 2016-02-25 | 2020-01-02 | Asceneuron S. A. | Glycosidase inhibitors |
US11261183B2 (en) | 2016-02-25 | 2022-03-01 | Asceneuron Sa | Sulfoximine glycosidase inhibitors |
AU2017222962B2 (en) | 2016-02-25 | 2021-03-25 | Asceneuron S. A. | Acid addition salts of piperazine derivatives |
MA43677A (fr) | 2016-02-25 | 2018-11-28 | Asceneuron Sa | Inhibiteurs de glycosidases |
EP3672959A1 (en) | 2017-08-24 | 2020-07-01 | Asceneuron SA | Linear glycosidase inhibitors |
US12016852B2 (en) | 2018-08-22 | 2024-06-25 | Asceneuron Sa | Pyrrolidine glycosidase inhibitors |
WO2020039028A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Tetrahydro-benzoazepine glycosidase inhibitors |
WO2020039029A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Spiro compounds as glycosidase inhibitors |
MX2021010314A (es) * | 2019-02-28 | 2021-11-12 | Kezar Life Sciences | Derivados de tiazol como inhibidores de la secreción de proteínas. |
US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
US11753413B2 (en) | 2020-06-19 | 2023-09-12 | Incyte Corporation | Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors |
WO2022006456A1 (en) | 2020-07-02 | 2022-01-06 | Incyte Corporation | Tricyclic pyridone compounds as jak2 v617f inhibitors |
KR20230057341A (ko) | 2020-07-02 | 2023-04-28 | 인사이트 코포레이션 | Jak2 v617f 억제제로서 삼환계 우레아 화합물 |
WO2022046989A1 (en) | 2020-08-27 | 2022-03-03 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
WO2022140231A1 (en) | 2020-12-21 | 2022-06-30 | Incyte Corporation | Deazaguaine compounds as jak2 v617f inhibitors |
JP2024507935A (ja) | 2021-02-25 | 2024-02-21 | インサイト・コーポレイション | Jak2 v617f阻害剤としてのスピロ環式ラクタム |
AU2023235313A1 (en) | 2022-03-17 | 2024-10-03 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
WO2024059212A2 (en) * | 2022-09-15 | 2024-03-21 | Vanderbilt University | 6,6 western core compounds as mglu5 negative allosteric modulators and methods of making and using the same |
WO2024059216A2 (en) * | 2022-09-15 | 2024-03-21 | Vanderbilt University | 6,6 southwestern core compounds as mglu5 negative allosteric modulators and methods of making and using the same |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060030584A1 (en) * | 2004-08-03 | 2006-02-09 | Hanson Gunnar J | 2,8-Disubstituted naphthyridine derivatives |
WO2006094237A2 (en) * | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Acridine and quinoline dervatives as sirtuin modulators |
CN101959865A (zh) * | 2008-02-28 | 2011-01-26 | 诺瓦提斯公司 | 作为法尼基焦磷酸合酶抑制剂的喹啉类化合物 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU740745B2 (en) * | 1997-12-11 | 2001-11-15 | Biochem Pharma Inc. | Antiviral compounds |
FR2827599A1 (fr) * | 2001-07-20 | 2003-01-24 | Neuro3D | Composes derives de quinoleine et quinoxaline,preparation et utilisations |
SE0103649D0 (sv) * | 2001-11-01 | 2001-11-01 | Astrazeneca Ab | Therapeutic quinoline compounds |
JP2006519846A (ja) * | 2003-03-10 | 2006-08-31 | シェーリング コーポレイション | 複素環式キナーゼインヒビター:使用および合成の方法 |
CA2723135A1 (en) * | 2008-05-01 | 2009-11-05 | Sirtris Pharmaceuticals, Inc. | Quenolines and related analogs as sirtuin modulators |
AU2009295948B2 (en) * | 2008-09-29 | 2013-12-05 | GlaxoSmithKline, LLC | Quinazolinone, quinolone and related analogs as sirtuin modulators |
-
2010
- 2010-03-02 WO PCT/US2010/025963 patent/WO2010101949A1/en active Application Filing
- 2010-03-02 KR KR1020117023017A patent/KR20110128908A/ko not_active Application Discontinuation
- 2010-03-02 MX MX2011009213A patent/MX2011009213A/es not_active Application Discontinuation
- 2010-03-02 AU AU2010221417A patent/AU2010221417A1/en not_active Abandoned
- 2010-03-02 EP EP10749227A patent/EP2403833A4/en not_active Withdrawn
- 2010-03-02 CN CN2010800194505A patent/CN102414180A/zh active Pending
- 2010-03-02 EA EA201171098A patent/EA201171098A1/ru unknown
- 2010-03-02 BR BRPI1011477A patent/BRPI1011477A2/pt not_active Application Discontinuation
- 2010-03-02 CA CA2754058A patent/CA2754058A1/en not_active Abandoned
- 2010-03-02 JP JP2011553053A patent/JP2012519211A/ja not_active Withdrawn
-
2011
- 2011-09-01 IL IL214943A patent/IL214943A0/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060030584A1 (en) * | 2004-08-03 | 2006-02-09 | Hanson Gunnar J | 2,8-Disubstituted naphthyridine derivatives |
WO2006094237A2 (en) * | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Acridine and quinoline dervatives as sirtuin modulators |
CN101959865A (zh) * | 2008-02-28 | 2011-01-26 | 诺瓦提斯公司 | 作为法尼基焦磷酸合酶抑制剂的喹啉类化合物 |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105143222A (zh) * | 2013-03-14 | 2015-12-09 | 默克专利有限公司 | 糖苷酶抑制剂 |
CN105143222B (zh) * | 2013-03-14 | 2018-02-02 | 默克专利有限公司 | 糖苷酶抑制剂 |
CN105764901A (zh) * | 2013-11-12 | 2016-07-13 | 豪夫迈·罗氏有限公司 | 作为用于治疗神经变性疾病的神经源性药的吡啶并[4,3-b]吡嗪-2-甲酰胺 |
US9670206B2 (en) | 2013-11-12 | 2017-06-06 | Hoffmann-La Roche Inc. | Pyrido[4,3-B]pyrazine-2-carboxamides as neurogenic agents for the treatment of neurodegenerative disorders |
CN105764901B (zh) * | 2013-11-12 | 2018-06-22 | 豪夫迈·罗氏有限公司 | 作为用于治疗神经变性疾病的神经源性药的吡啶并[4,3-b]吡嗪-2-甲酰胺 |
CN104592109A (zh) * | 2015-01-19 | 2015-05-06 | 湖南华腾制药有限公司 | 一种8-溴喹啉衍生物的制备方法 |
CN110964011A (zh) * | 2019-12-16 | 2020-04-07 | 诚达药业股份有限公司 | 一种8-氯-1,7-萘啶-3-甲醛的合成方法 |
CN110964011B (zh) * | 2019-12-16 | 2022-06-21 | 诚达药业股份有限公司 | 一种8-氯-1,7-萘啶-3-甲醛的合成方法 |
CN117362286A (zh) * | 2023-12-08 | 2024-01-09 | 清华大学 | 具有sirt6激动活性的化合物及其用途 |
CN117362286B (zh) * | 2023-12-08 | 2024-03-12 | 清华大学 | 具有sirt6激动活性的化合物及其用途 |
Also Published As
Publication number | Publication date |
---|---|
AU2010221417A1 (en) | 2011-09-22 |
CA2754058A1 (en) | 2010-09-10 |
KR20110128908A (ko) | 2011-11-30 |
EA201171098A1 (ru) | 2012-04-30 |
EP2403833A4 (en) | 2012-08-29 |
MX2011009213A (es) | 2011-12-14 |
WO2010101949A1 (en) | 2010-09-10 |
EP2403833A1 (en) | 2012-01-11 |
BRPI1011477A2 (pt) | 2016-03-22 |
JP2012519211A (ja) | 2012-08-23 |
IL214943A0 (en) | 2011-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102414180A (zh) | 作为沉默调节蛋白调节剂的8-取代的喹啉及相关的类似物 | |
CN102227417B (zh) | 作为沉默调节蛋白调节剂的色烯酮类似物 | |
CN102143957B (zh) | 作为沉默调节蛋白调节剂的苯并咪唑类和相关的类似物 | |
CN102388054B (zh) | 噻唑并吡啶沉默调节蛋白调节剂的化合物 | |
CN102083438B (zh) | 作为沉默信息调节因子的调节剂的喹啉和相关类似物 | |
CN102307871A (zh) | 作为沉默调节蛋白调节剂的异吲哚啉酮和相关的类似物 | |
CN102725291B (zh) | 作为沉默调节蛋白调节剂的双环吡啶和相关的类似物 | |
CN102272119A (zh) | 作为沉默调节蛋白调节剂的吡啶、双环吡啶和相关的类似物 | |
CN103998451A (zh) | 用作沉默调节蛋白调节剂的取代的双环氮杂杂环化合物和类似物 | |
CN102985553B (zh) | 沉默调节蛋白活化剂和活化测定 | |
CN102317284A (zh) | 作为沉默调节蛋白调节剂的酞嗪酮和相关的类似物 | |
CN101910184A (zh) | 可溶性噻唑并吡啶 | |
JP2012500202A (ja) | サーチュインモジュレーターとしてのベンゾオキサゾール、ベンズチアゾールおよび関連するアナログ | |
CN101918371A (zh) | 作为瑟土因调节剂的酰胺衍生物 | |
JP2011521960A (ja) | サーチュイン調節薬としてのイミダゾピリジンおよび関連する類似体 | |
CN104011053A (zh) | 用作沉默调节蛋白调节剂的取代的双环氮杂杂环化合物和类似物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120411 |